Fundamentals-based quality & risk · not a recommendation
Raw blend 76 capped to 72 by a red flag.
Raw blend 76 → capped to 72
Procter & Gamble Health Ltd scores 72/100 (Quality) on the Orion Score — strong business quality (87), weak growth (35) and strong balance-sheet safety (94). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
56/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹370.45 | ₹94.6 | 34.9% | ₹56.99 |
| Q3 2026 | ₹373.86 | ₹77.59 | 28.0% | ₹46.74 |
| Q2 2026 | ₹324.92 | ₹88.54 | 35.1% | ₹53.54 |
| Q1 2026 | ₹338.74 | ₹66.18 | 25.1% | ₹39.87 |
| Q4 2025 | ₹310.99 | ₹61.18 | 24.3% | ₹36.86 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2026 | ₹1,407.97 | ₹326.91 | ₹474 | 30.8% |
| FY 2024 | ₹1,129.49 | ₹200.98 | ₹301.44 | 24.7% |
| FY 2023 | ₹1,205.86 | ₹229.47 | ₹343.07 | 24.5% |
| FY 2022 | ₹1,092.04 | ₹192.52 | ₹280.87 | 22.7% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| PGHL ★ | — | 31.45 | 73.85% | 61.59% | 0.02x | 34.94% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹90,029 Cr | 25.94 | 12.55% | 9.93% | 0.21x | 15.11% |
| ABBOTINDIA | ₹57,724 Cr | 36.63 | 36.14% | 34.46% | 0.04x | 27.01% |
| AJANTPHARM | ₹41,836 Cr | 39.55 | 27.99% | 25.39% | 0.06x | 51.40% |
All values in ₹ Crores
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total Assets | ₹794.36 | ₹1,101.19 | ₹888.12 | ₹986.16 |
| Equity | ₹538.24 | ₹750.89 | ₹616.49 | ₹703.71 |
| Total Debt | ₹9.56 | ₹12 | ₹2.83 | ₹7.61 |
| Cash | ₹238.5 | ₹435.05 | ₹319.4 | ₹464.05 |
| Net Debt | — | — | — | — |
| Working Capital | ₹305.31 | ₹492.2 | ₹376.14 | ₹488.17 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 52.2% ↑ | 8.56% ↑ | 7.01% ↓ | 32.23% ↑ |
| Q3 FY2026 | 51.82% | 6.97% ↓ | 13.84% ↓ | 27.37% ↑ |
| Q2 FY2026 | 51.82% | 7.24% ↑ | 13.9% ↓ | 27.05% ↑ |
| Q1 FY2026 | 51.82% | 6.99% ↑ | 14.15% ↓ | 27.03% ↓ |
| Q4 FY2025 | 51.82% | 6.86% ↓ | 14.21% ↓ | 27.11% ↑ |
| Q3 FY2025 | 51.82% | 7.01% ↑ | 14.71% ↓ | 26.47% ↓ |
| Q2 FY2025 | 51.82% | 6.61% ↑ | 14.84% ↑ | 26.74% ↓ |
| Q1 FY2025 | 51.82% | 6.39% | 14.56% | 27.24% |
| Ex-Date | Action | Details |
|---|---|---|
| 2026-08-21 | DIVIDEND | Dividend - Rs 45 Per Share |
| 2026-02-12 | DIVIDEND | Interim Dividend - Rs 110 Per Share & Special Dividend Rs 50 Per Share |
16 mutual fund schemes
Ask: "Is Procter & Gamble Health Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Procter & Gamble Health Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE199A01012. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.